LEGN – legend biotech corporation - american depositary shares (US:NASDAQ)
Stock Stats
News
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma [Yahoo! Finance]
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
Legend Biotech Co. (NASDAQ: LEGN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $83.00 price target on the stock.
Legend Biotech Co. (NASDAQ: LEGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Form 6-K Legend Biotech Corp For: Dec 09
Form 144 Legend Biotech Corp Filed by: Heyman Tomas J.
Form SC 13G/A Legend Biotech Corp Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form S-8 Legend Biotech Corp
Form SC 13G/A Legend Biotech Corp Filed by: FMR LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.